Early stage NSCLC

80P - High blood platelets levels (BPL): A prognostic factor in patients with early or locally advanced non-small cell lung cancer (NSCLC)

Authors
  • J. Cordoba Ortega (Lleida, Spain)
  • A. Salud (Lerida, Spain)
  • S. Morales (Lerida, Spain)
  • J. Veas (Lerida, Spain)
  • A. Rodriguez (Lerida, Spain)
Speakers
  • J. Cordoba Ortega (Lleida, Spain)

Previous ePoster

No ePoster preview available
15P - TTF1 status in non-small cell lung cancer adenocarcinoma: A prognostic factor

Next ePosters
169P_PR - Benefit of immunotherapy (IT) in advanced non-small cell lung cancer (NSCLC) in elderly patients (EP)
73P - Utilization rates of stereotactic body radiation therapy for the treatment of stage I NSCLC in three European countries
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
36P - Can a BALF profile distinguish hot vs cold lung tumors?
8P - Role of chemokines in resectable non-small cell lung cancer (NSCLC)
129P - Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors
154P - Renal toxicity from platinum/pemetrexed and pembrolizumab in the era of combination therapy
47P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with NSCLC in Sweden: A SCAN-LEAF study analysis from the I-O Optimise initiative
3P - Notable variation of molecular testing in metastatic lung cancer in the Netherlands